Régions 5' non traduites : Questions médicales fréquentes
Nom anglais: 5' Untranslated Regions
Descriptor UI:D020121
Tree Number:G05.360.340.024.340.137.910.885
Termes MeSH sélectionnés :
Controlled Substances
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions 5' non traduites : Questions médicales les plus fréquentes",
"headline": "Régions 5' non traduites : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions 5' non traduites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions 5' non traduites"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Régions non traduites",
"url": "https://questionsmedicales.fr/mesh/D020506",
"about": {
"@type": "MedicalCondition",
"name": "Régions non traduites",
"code": {
"@type": "MedicalCode",
"code": "D020506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions 5' non traduites",
"alternateName": "5' Untranslated Regions",
"code": {
"@type": "MedicalCode",
"code": "D020121",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nicola Whiffin",
"url": "https://questionsmedicales.fr/author/Nicola%20Whiffin",
"affiliation": {
"@type": "Organization",
"name": "National Heart and Lung Institute and MRC London Institute of Medical Science, Imperial College London, London W12 0NN, UK."
}
},
{
"@type": "Person",
"name": "Olga A Nikolaitchik",
"url": "https://questionsmedicales.fr/author/Olga%20A%20Nikolaitchik",
"affiliation": {
"@type": "Organization",
"name": "Viral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Vinay K Pathak",
"url": "https://questionsmedicales.fr/author/Vinay%20K%20Pathak",
"affiliation": {
"@type": "Organization",
"name": "Viral Mutation Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Wei-Shau Hu",
"url": "https://questionsmedicales.fr/author/Wei-Shau%20Hu",
"affiliation": {
"@type": "Organization",
"name": "Viral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA."
}
},
{
"@type": "Person",
"name": "William E Tapprich",
"url": "https://questionsmedicales.fr/author/William%20E%20Tapprich",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, University of Nebraska at Omaha, Omaha, Nebraska, USA wtapprich@unomaha.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.",
"datePublished": "2023-01-02",
"url": "https://questionsmedicales.fr/article/36595589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5435/JAAOS-D-22-00458"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychomodulatory substances: New legislative framework for control of psychoactive substances in Czechia.",
"datePublished": "2024-10-09",
"url": "https://questionsmedicales.fr/article/39388916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugpo.2024.104603"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37348270",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugalcdep.2023.110819"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35947832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5435/JAAOS-D-22-00433"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents.",
"datePublished": "2024-05-31",
"url": "https://questionsmedicales.fr/article/38818605",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/jme.2024.60"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Régions non traduites",
"item": "https://questionsmedicales.fr/mesh/D020506"
},
{
"@type": "ListItem",
"position": 9,
"name": "Régions 5' non traduites",
"item": "https://questionsmedicales.fr/mesh/D020121"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions 5' non traduites - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions 5' non traduites",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions 5' non traduites",
"description": "Comment identifier les 5' UTR dans un gène ?\nQuels tests sont utilisés pour étudier les 5' UTR ?\nLes 5' UTR sont-elles visibles sur des électrophorèses ?\nPeut-on détecter des mutations dans les 5' UTR ?\nQuel rôle jouent les 5' UTR dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions 5' non traduites",
"description": "Les 5' UTR sont-elles liées à des symptômes cliniques ?\nQuels symptômes peuvent indiquer un problème avec les 5' UTR ?\nLes 5' UTR affectent-elles la réponse aux traitements ?\nPeut-on relier les 5' UTR à des syndromes spécifiques ?\nLes 5' UTR sont-elles impliquées dans des cancers ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions 5' non traduites",
"description": "Peut-on prévenir les anomalies des 5' UTR ?\nY a-t-il des facteurs environnementaux affectant les 5' UTR ?\nComment le mode de vie influence-t-il les 5' UTR ?\nLes dépistages génétiques aident-ils à prévenir les problèmes liés aux 5' UTR ?\nLes vaccinations influencent-elles les 5' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions 5' non traduites",
"description": "Comment les traitements ciblent-ils les 5' UTR ?\nLes médicaments peuvent-ils interagir avec les 5' UTR ?\nY a-t-il des traitements pour corriger les anomalies des 5' UTR ?\nLes traitements ciblant les 5' UTR sont-ils efficaces ?\nLes 5' UTR influencent-elles la résistance aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions 5' non traduites",
"description": "Quelles complications peuvent survenir avec des anomalies des 5' UTR ?\nLes anomalies des 5' UTR peuvent-elles entraîner des complications héréditaires ?\nComment les 5' UTR affectent-elles le pronostic des maladies ?\nLes complications liées aux 5' UTR sont-elles réversibles ?\nLes 5' UTR sont-elles impliquées dans des complications post-thérapeutiques ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions 5' non traduites",
"description": "Quels sont les facteurs de risque pour les anomalies des 5' UTR ?\nL'âge est-il un facteur de risque pour les anomalies des 5' UTR ?\nLes habitudes alimentaires influencent-elles les 5' UTR ?\nLe stress peut-il affecter les 5' UTR ?\nLes infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les 5' UTR dans un gène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les 5' UTR peuvent être identifiées par séquençage d'ARN et analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les 5' UTR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le RT-PCR et les analyses de l'expression génique."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles visibles sur des électrophorèses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être visualisées sur des gels d'électrophorèse après amplification."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les 5' UTR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être détectées par séquençage ciblé des régions 5' UTR."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les 5' UTR dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles influencent la régulation de l'expression génique, affectant le diagnostic de maladies."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles liées à des symptômes cliniques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans les 5' UTR peuvent entraîner des symptômes variés selon le gène affecté."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les 5' UTR ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des troubles métaboliques ou des maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Les 5' UTR affectent-elles la réponse aux traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations dans les 5' UTR peuvent influencer l'efficacité des traitements médicamenteux."
}
},
{
"@type": "Question",
"name": "Peut-on relier les 5' UTR à des syndromes spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations dans les 5' UTR sont associées à des syndromes génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles impliquées dans des cancers ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations dans les 5' UTR peuvent contribuer à la carcinogenèse dans certains cancers."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des 5' UTR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des conseils génétiques et un suivi médical pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux affectant les 5' UTR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des gènes liés aux 5' UTR."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il les 5' UTR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque d'anomalies génétiques, y compris celles des 5' UTR."
}
},
{
"@type": "Question",
"name": "Les dépistages génétiques aident-ils à prévenir les problèmes liés aux 5' UTR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage génétique peut identifier les risques et permettre une intervention précoce."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles les 5' UTR ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations n'affectent pas directement les 5' UTR, mais protègent contre certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment les traitements ciblent-ils les 5' UTR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des oligonucléotides peuvent cibler les 5' UTR pour moduler l'expression."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils interagir avec les 5' UTR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent moduler l'activité des 5' UTR, influençant la traduction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements pour corriger les anomalies des 5' UTR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de thérapie génique sont en développement pour corriger ces anomalies."
}
},
{
"@type": "Question",
"name": "Les traitements ciblant les 5' UTR sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité dépend du type de mutation et du contexte biologique de la maladie."
}
},
{
"@type": "Question",
"name": "Les 5' UTR influencent-elles la résistance aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations dans les 5' UTR peuvent être liées à la résistance aux traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des 5' UTR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des maladies métaboliques, des cancers ou des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les anomalies des 5' UTR peuvent-elles entraîner des complications héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent être transmises et causer des complications héréditaires."
}
},
{
"@type": "Question",
"name": "Comment les 5' UTR affectent-elles le pronostic des maladies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les variations dans les 5' UTR peuvent influencer le pronostic et la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Les complications liées aux 5' UTR sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la maladie."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles impliquées dans des complications post-thérapeutiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des modifications dans les 5' UTR peuvent contribuer à des complications après traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des 5' UTR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et des mutations."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les anomalies des 5' UTR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations dans les 5' UTR et d'autres gènes."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles les 5' UTR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires peuvent affecter l'expression des gènes, y compris les 5' UTR."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter les 5' UTR ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut influencer l'expression génique et potentiellement affecter les 5' UTR."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent induire des modifications dans les 5' UTR, augmentant les risques."
}
}
]
}
]
}
The purpose of this study is to identify the risk factors for prolonged opioid use after surgery in geriatric hip fracture patients and the effects of prolonged use on mortality and readmission rates....
An institutional registry was queried for all patients older than 65 years who underwent surgical treatment of a hip fracture between January 2016 and June 2017. Using the Controlled Substance Utiliza...
Of 500 patients who underwent hip-fracture surgery during the study period, a total of 322 had complete Controlled Substance Utilization Review and Evaluation System data. 36.0% (116) were OE, and 64....
Opioid use in geriatric hip fracture patients is high both preoperatively and postoperatively. Opioid exposed patients and patients on antidepressants are more likely to continue opioids at 6 months. ...
Level III....
This article challenges drug prohibition advocated by UN conventions as the prevailing regulatory model for psychoactive substances, highlighting its ineffectiveness, harmfulness and outdated nature. ...
Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence in Mexico has not been assessed. Our ethnographic team ...
To characterize the availability of counterfeit and authentic controlled substances at pharmacies in Northern Mexico available to English-speaking tourists without a prescription....
We employed an iterative, exploratory, mixed methods design. Longitudinal ethnographic data was used to characterize tourist-oriented micro-neighborhoods and guide the selection of n=40 pharmacies in ...
Of n=40 pharmacies, one or more of the requested controlled substances could be obtained with no prescription (as single pills or in bottles) at 28 (70.0%) and as single pills at 19 (47.5%). Counterfe...
The availability of fentanyl-, heroin-, and methamphetamine-based counterfeit medications in tourist-oriented independent pharmacies in Northern Mexico represents a public health risk, and occurs in t...
The United States opioid epidemic is a well-documented crisis stemming from increased prescriptions of narcotics. Online prescription drug monitoring programs (PDMPs) are a potential resource to mitig...
Patients who underwent a single-level lumbar fusion between August 27, 2017, and August 31, 2020, were identified and placed categorically into one of two cohorts: an "early adoption" cohort, Septembe...
No significant difference was observed in preoperative opioid prescriptions between the early and late adoption cohorts. The late adoption group independently predicted decreased postoperative opioid ...
PDMP implementation was associated with decreased postoperative opioid prescription patterns but not preoperative opioid prescribing behaviors....
4....
U.S. law imposes strict recording and reporting requirements on all entities that manufacture and distribute controlled substances. As a result, the prescription opioid crisis has unfolded in a data-s...
There is concern around non-prescribed benzodiazepine use, particularly with increasing detections of counterfeit products containing high-risk novel compounds. The aims of this study were to investig...
Data were collected from a sample of Australians who inject drugs or use ecstasy and/or other illicit stimulants on a monthly or more frequent basis, and who reported past 6-month use of non-prescribe...
Amongst participants who injected drugs, 71% reported that their last non-prescribed benzodiazepines were diverted from a known/trusted prescription, compared to 59% of participants who used ecstasy/o...
Most participants obtained substances sold as classic/registered benzodiazepines, mostly via diverted prescriptions, with a substantial minority potentially unaware of counterfeits circulating. While ...
Tools that are directly integrated with the electronic health record (EHR) workflow can reduce the hassle cost of certain guideline-concordant practices, such as querying a prescription drug monitorin...
To investigate the effect of integrating access to a PDMP within the EHR on the frequency of program queries by primary care clinicians....
The PRINCE (Prescribing Interventions for Chronic Pain Using the Electronic Health Record) randomized trial used a factorial cluster design at the clinic level in 43 primary care clinics in Minnesota....
Single sign-on access to the Minnesota PDMP was integrated into the EHR, allowing clinicians to query a patient's controlled substance prescription and dispensing history as recorded in the Minnesota ...
Monthly PDMP query counts for primary care clinicians, overall and by modality (EHR-based, web-based, via a clinical delegate), adjusted for clinician characteristics, including type (physician, nurse...
Of the 43 participating clinics with 309 clinicians, 21 clinics with 161 clinicians (102 [63.4%] women; 114 [70.8%] physicians; tenure, 10.6 [4.4] years) received the PDMP integration intervention. Ba...
This cluster randomized clinical trial found that integrating access to the PDMP in the EHR increased PDMP-querying rates, suggesting that direct access reduced hassle costs and can dramatically impro...
ClinicalTrials.gov Identifier: NCT04601506....
While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool ...
Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant...
There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific t...
Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities....
A new FHIR-based (fast healthcare interoperability resource), EHR-integrated (electronic health record) application was created that embeds directly into prescribers' workflows. The intervention autom...
911 Good Samaritan Laws (GSLs) confer limited legal immunity to bystanders in possession of controlled substances who report emergency overdoses. While these laws may decrease opioid overdose mortalit...
We identified all state GSLs and their legislative history, characterizing features into four categories using a novel framework: breadth of protected activities, burden placed on Good Samaritans, str...
GSLs vary substantially across states and time. Protections depend on the quantity of substances involved and may extend to the person experiencing the overdose or persons reporting their own overdose...
States offer Good Samaritans substantially different protections even when the statutes confer nominally comparable immunities. Accommodating this heterogeneity will enhance the validity of future stu...